Clinical Trials

Overview

About this study

The purpose of this study is to evaluate the application of machine learning models, DULCE and ACE scores, in the identification of advanced liver fibrosis (stage 3-4) and clinically significant portal hypertension, respectivelly

The objectives of this study are to determine if the DULCE score can accurately predict advanced liver fibrosis (stage 3-4) using 6-lead and 12-lead ECGs, to assess the performance of ACE score for detection of Clinically Significant Portal Hypertension, using 6-lead and 12-lead ECG, and to assess and validate the performance of DULCE and ACE scores in 6-lead ECGs compared to 12-lead ECGs.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Participating Mayo Clinic locations

More information